Linden Capital Partners Acquires Alcresta Therapeutics, Inc.

Alcresta TherapeuticsAvery WilliamsMarch 12, 20242024

Alcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients Ages 2 to 5 Years

Alcresta TherapeuticsAvery WilliamsAugust 31, 20232023

Alcresta Therapeutics Announces Publication of Cystic Fibrosis Foundation Position Paper Confirming Inline Enzyme Cartridges are Safe and Effective

Alcresta TherapeuticsAvery WilliamsJuly 25, 20232023

Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis

Alcresta TherapeuticsAvery WilliamsFebruary 24, 20212021

Alcresta announces the issuance of a permanent and unique billing code by the Centers for Medicare and Medicaid Services (CMS) for RELiZORB

Alcresta Therapeutics, Inc. announced the issuance of a permanent and unique billing code by the Centers for Medicare and Medicaid Services (CMS) for RELiZORB.